Evolva Acquires Resveratrol Programme From Fluxome
date:Dec 10, 2012
Neil Goldsmith, CEO of Evolva said. We see this as a highly attractive asset acquisition on terms that work well for Evolva shareholders. Resveratrol is an on-market functional ingredient that perfectly fits our focus area of health, nutrition and wellness. It has particular benefits in areas such as vascular inflammation, an area of great interest to many companies and one we understand well given our knowledge from EV-077.

Like our current product portfolio, resveratrol is produced by fermen
1/16 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/26 07:00